药品注册申请号:019430
申请类型:NDA (新药申请)
申请人:MYLAN SPECIALITY LP
申请人全名:MYLAN SPECIALTY LP
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 EPIPEN EPINEPHRINE INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 0.3MG/DELIVERY Yes Yes AB 1987/12/22 1987/12/22 Prescription
002 EPIPEN JR. EPINEPHRINE INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 0.15MG/DELIVERY Yes Yes AB 1987/12/22 Prescription
003 EPIPEN E Z PEN EPINEPHRINE INJECTABLE;INTRAMUSCULAR 0.3MG/DELIVERY No No None 1995/08/03 Discontinued
004 EPI E Z PEN JR EPINEPHRINE INJECTABLE;INTRAMUSCULAR 0.15MG/DELIVERY No No None 1995/08/03 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/02/10 SUPPL-106(补充) Approval Labeling STANDARD
2020/12/24 SUPPL-91(补充) Approval Labeling STANDARD
2020/06/17 SUPPL-89(补充) Approval Labeling STANDARD
2020/01/31 SUPPL-82(补充) Approval Labeling STANDARD
2018/08/23 SUPPL-74(补充) Approval Labeling STANDARD
2017/04/28 SUPPL-67(补充) Approval Labeling STANDARD
2016/05/18 SUPPL-61(补充) Approval Labeling 901 REQUIRED
2016/03/03 SUPPL-60(补充) Approval Manufacturing (CMC) STANDARD
2014/07/17 SUPPL-58(补充) Approval Labeling STANDARD
2014/04/30 SUPPL-59(补充) Approval Labeling STANDARD
2013/12/13 SUPPL-57(补充) Approval Manufacturing (CMC) STANDARD
2013/11/08 SUPPL-56(补充) Approval Manufacturing (CMC) STANDARD
2013/09/16 SUPPL-55(补充) Approval Manufacturing (CMC) STANDARD
2013/07/23 SUPPL-54(补充) Approval Manufacturing (CMC) STANDARD
2012/08/20 SUPPL-53(补充) Approval Labeling STANDARD
2009/05/19 SUPPL-47(补充) Approval Labeling STANDARD
2008/09/26 SUPPL-44(补充) Approval Labeling STANDARD
2003/12/17 SUPPL-25(补充) Approval Labeling STANDARD
2002/12/19 SUPPL-18(补充) Approval Manufacturing (CMC) STANDARD
2002/08/21 SUPPL-17(补充) Approval Manufacturing (CMC) STANDARD
2002/06/28 SUPPL-16(补充) Approval Manufacturing (CMC) STANDARD
2002/04/16 SUPPL-15(补充) Approval Manufacturing (CMC) STANDARD
2002/02/20 SUPPL-14(补充) Approval Manufacturing (CMC) STANDARD
2001/08/27 SUPPL-12(补充) Approval Labeling STANDARD
2001/01/11 SUPPL-11(补充) Approval Manufacturing (CMC) STANDARD
2000/05/11 SUPPL-10(补充) Approval Manufacturing (CMC) STANDARD
1999/12/15 SUPPL-8(补充) Approval Manufacturing (CMC) STANDARD
1999/11/05 SUPPL-9(补充) Approval Manufacturing (CMC) STANDARD
1999/05/25 SUPPL-7(补充) Approval Manufacturing (CMC) STANDARD
1997/01/24 SUPPL-6(补充) Approval Manufacturing (CMC) STANDARD
1996/07/25 SUPPL-5(补充) Approval Manufacturing (CMC) STANDARD
1995/08/03 SUPPL-4(补充) Approval Manufacturing (CMC) STANDARD
1989/03/02 SUPPL-1(补充) Approval Labeling
1987/12/22 ORIG-1(原始申请) Approval Type 5 - New Formulation or New Manufacturer STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 7449012 2025/09/11 Y PDF格式
7794432 2025/09/11 Y PDF格式
8048035 2025/09/11 Y 2011/11/25 PDF格式
8870827 2025/09/11 Y 2014/10/30 PDF格式
9586010 2025/09/11 Y 2017/05/12 PDF格式
002 7449012 2025/09/11 Y PDF格式
7794432 2025/09/11 Y PDF格式
8048035 2025/09/11 Y PDF格式
8870827 2025/09/11 Y 2014/10/30 PDF格式
9586010 2025/09/11 Y 2017/05/12 PDF格式
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:EPINEPHRINE 剂型/给药途径:INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 规格:0.3MG/DELIVERY 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
019430 001 NDA EPIPEN EPINEPHRINE INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 0.3MG/DELIVERY Prescription Yes Yes AB 1987/12/22 MYLAN SPECIALITY LP
090589 001 ANDA EPINEPHRINE (AUTOINJECTOR) EPINEPHRINE INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 0.3MG/DELIVERY Prescription No No AB 2018/08/16 TEVA PHARMS USA
活性成分:EPINEPHRINE 剂型/给药途径:INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 规格:0.15MG/DELIVERY 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
019430 002 NDA EPIPEN JR. EPINEPHRINE INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 0.15MG/DELIVERY Prescription Yes Yes AB 1987/12/22 MYLAN SPECIALITY LP
090589 002 ANDA EPINEPHRINE (AUTOINJECTOR) EPINEPHRINE INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 0.15MG/DELIVERY Prescription No No AB 2018/08/16 TEVA PHARMS USA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database